BIOMARKERS FOR COMBINED THERAPY INCLUDING LENVATINIB AND EVEROLIMUS Russian patent published in 2021 - IPC G01N33/574 G01N33/68 A61K31/47 A61K31/436 A61P35/00 

FIELD: medicine.

SUBSTANCE: set of inventions relates to medicine, in particular to oncology, and is intended for the treatment of renal cell cancer in a human subject. A method for identifying a human subject who suffers from, is suspected of, or is in danger of renal cell cancer development requiring combination therapy containing lenvatinib or a pharmaceutically acceptable salt thereof and an everolimus, includes the analysis of a biological sample taken from a human subject prior to the preparation thereof of a combination therapy, including lenvatinib or its pharmaceutically acceptable salt and everolimus, and the determination that the concentration of angiopoetin-2 protein (Ang2) in the biological sample above the control level; and the identification of a human subject with a high concentration of Ang2 protein in the biological sample as needing a combination therapy that includes lenvatinib or its pharmaceutically acceptable salt and everolimus. The other embodiment is the use of lenvatinib or its pharmaceutically acceptable salt in combination with everolimus in the treatment of renal cell cancer in a human subject, where the human subject is identified as a subject by the above-mentioned method, who needs a combination therapy that includes lenvatinib or its pharmaceutically acceptable salt and everolimus.

EFFECT: use of set of inventions enables increasing effectiveness of the treatment of renal cell cancer in a human subject.

13 cl, 2 dwg, 1 ex